【レポートの概要（一部）】
1. Executive Summary
1.1 Overview of Findings
1.2 Structure of the Report
1.3 Research and Analysis Methods
2. Introduction to Antibacterials and Antibacterial Drugs
2.1 Bacterial Infections
2.1.1 How Bacteria Cause Infections
2.1.2 Classification of Bacteria
2.1.3 Types of Bacterial Infection
2.1.4 Leading Causative Bacterium
2.1.5 Incidence and Mortality Profiles for Common Bacterial Infection
2.2 Treating Infections
2.2.1 The History of Antibacterial Drug Development
2.2.2 Mechanisms of Action
2.2.3 Leading Classes of Antibacterial Compounds
2.2.3.1 Cephalosporins
2.2.3.2 Penicillins
2.2.3.3 Carbapenems
2.2.3.4 Fluoroquinolones
2.2.3.5 Macrolides
2.3 Antibacterial Drugs Resistance
3. Antibacterial Drugs: World Market, 2014-2024
3.1 Antibacterials Revenues Plateau between 2009 and 2013
3.1.1 Antibacterial Drugs – Market Segmentation
3.2 Antibacterial Market Forecast, 2014-2024: Decline in Revenues for Fluoroquinolones
3.2.1 Drivers and Restraints in the Antibacterial Market, 2014-2024
3.2.2 Generic Erosion and Prescription Control will Limit Market Growth
3.2.3 Changes in Sector Market Shares, 2014-2024
3.3 Pfizer is the Clear Leader in the Antibacterial Drugs Market
3.3.1 Pfizer Usurped by Cubist as the Leading Antibacterial Drug Manufacturer – Company Revenue Forecasts 2014-2024
3.3.2 Fragmented Market to Fracture Further
3.3.3 Leading Firms without Leading R&D Pipelines
4. Cephalosporin Market Forecast, 2014-2024
4.1 Cephalosporin Market 2012-2013 – No Dominant Brands
4.2 Late-Stage Cephalosporins to Gain Market Share Between 2014 and 2024
4.3 Basilea, Cubist, and Forest Labs to Lead Cephalosporin Market Between 2014 and 2024
4.3.1 Drivers and Restraints in the Cephalosporins Market, 2014-2024
4.3.2 Cephalosporins Lack Market Exclusivity
4.3.3 Strong Pipeline for Novel Cephalosporins
4.4 Rocephin (Roche) – The Only Treatment for Gonorrhoea in the US
4.4.1 Off Patent but not Forgotten
4.4.2 Declining Revenues Owing to Competition – Forecast 2014-2024
4.5 Sulperazon – India’s Leading Treatment for RTIs and UTIs
4.5.1 Continued Growth in the Emerging Markets, Revenue Forecast 2014-2024
4.6 Zinnat/Ceftin – GSK’s Established Cephalosporin
4.6.1 Continued Decline in Revenue – Forecast 2014-2024
4.7 Meiact – A Broad Range Community Antibiotic
4.7.1 Minor Spectracef Sales in the US Leads to Pass the Product
4.7.2 Competition in Japan to Hinder Growth – Revenue Forecast 2014-2024
4.8 Flomox – Shionogi’s Third-Generation Cephalosporin
4.8.1 Patent Issues and Litigation
4.8.2 Genericisation and Safety to Restrict Sales – Forecast 2014-2024
4.9 Zinforo/Teflaro (Ceftaroline Fosamil): The First of the Fifth-Generation Cephalosporins
4.9.1 Unmet Needs in Pneumonia to Drive Growth – Revenue Forecast 2014-2024
4.10 Zeftera (Ceftobiprole): Approved for Pneumonia in Europe
4.10.1 Future Sales Dictated by US Approval – Revenue Forecast 2014-2024
4.11 CXA-201 (Ceftrolozane-Tazobactam): The Next Blockbuster Antibacterial
4.11.1 Broad Label and Spectrum of Activity Leads to Rapid Uptake – Revenue Forecast 2014-2024
4.12 CAZ-AVI (Ceftazidime-Avibactam): Forest Labs to Enter the Market on Phase II Data
4.12.1 Competition from CXA-201 to Limit Sales – Forecast 2014-2024
5. Penicillin Market Forecast, 2014-2024
5.1 Generics and Augmenting Dominate the Penicillins Market in 2012 and 2013
5.2 Augmentin to lose its Dominance over the Coming 10 Years – Market Shares for Penicillin Drugs, 2014-2024
5.3 Penicillin Antibacterials: Market Forecast 2014-2024
5.4 Drivers and Restraints on the Penicillin Market 2014-2024
5.5 Augmentin – Blockbuster Facing Generic Competition
5.5.1 Augmentin Recalled in Asian and Middle Eastern Markets
5.5.2 Stable Revenues in Spite of Generic Competition
5.5.3 Revenue Forecast 2014-2024
5.6 Zosyn/Tazocin (Piperacillin-Tazobactam) – Pneumonia Therapeutic
5.6.1 Patent Expiry and Revenue Extension for Pfizer
5.6.2 Historic and Current Revenue Performance
5.6.3 Revenue Forecast 2014-2024
5.7 Unasyn – Gram-negative and Positive Antibiotic
5.7.1 Consistently Falling Revenues – Forecast 2014-2024
5.8 Amoxil (Amoxicillin) – A Historic Antibacterial Brand
5.8.1 Marginal Decline in Revenue – Forecast 2014-2024
5.9 Generic Amoxicillin
5.9.1 Revenue Forecast 2014-2024
5.10 Generic Amoxicillin-Clavulanic Acid
5.10.1 Revenue Forecast 2014-2024
6. Fluoroquinolone Market Forecast, 2014-2024
6.1 The Fluoroquinolone Market 2012-2013
6.2 Changing Market Share for Fluoroquinolone Antibacterials 2014-2024
6.3 Fluoroquinolone Antibacterial Drugs: Market Forecast 2014-2024
6.4 Trends in the Fluoroquinolone Market
6.4.1 Safety Fears for Fluoroquinolones
6.4.2 Avelox Patent Cliff
6.4.3 Inhaled Fluoroquinolone Formulations
6.5 Fluoroquinolone Market Forecast 2014-2024
6.6 Avelox
6.6.1 Safety Profile Hampers Sales
6.6.2 Generic Competition
6.6.3 Revenue Forecast 2014-2024
6.7 Cravit and Levaquin
6.7.1 Generic Competition Affecting Revenue Worldwide
6.7.2 Lifecycle Management for Cravit and Levaquin
6.7.3 Revenue Forecast 2014-2024
6.8 Vigamox
6.8.1 Branded and Generic Challenges 2009-2012
6.8.2 Moxeza: A Next-Generation Form of Vigamox
6.8.3 Revenue Forecast 2014-2024
6.9 Cirpodex and Cipro – Two Preparations of Ciprofloxacin
6.9.1 Ciprodex: A Second-Generation Ophthalmic Antibiotic
6.9.1.1 Revenue Forecast 2014-2024
6.9.2 Cipro Revenue Forecast 2013-2023: Continued Generic Erosion
6.10 Geninax
6.10.1 Revenue Forecast 2014-2024
6.11 Delafloxacin
6.11.1 Revenue Forecast 2014-2024
7. Macrolide Market Forecast, 2014-2024
7.1 Macrolide Market in 2012-2013
7.2 Changing Market Share for Macrolides, 2014-2024
7.3 Macrolide Antibacterials: Market Forecast 2014-2024
7.4 Trends in the Macrolide Market
7.5 Biaxin/Clarith
7.5.1 Revenue 2012-2013
7.5.2 Lifecycle Management for Continued Market Presence
7.5.3 Revenue Forecast 2014-2024
7.6 Zithromax
7.6.1 Concerns Over Safety and Marketing in the US
7.6.2 Effectiveness in Drug-Resistant Strains
7.6.3 Revenue Forecast 2014-2024
7.7 Dalacin
7.7.1 Revenue Forecast 2014-2024
7.8 Dificid
7.8.1 Rapid Uptake Slowed by High Cost
7.8.2 New Approvals and Expanded Indications
7.8.3 Revenue Forecast 2014-2024
7.9 Solit
7.9.1 Revenue Forecast 2014-2024
8. Carbapenem Market Forecast, 2014-2024
8.1 Carbapenem Market 2012-2013
8.2 Changing Market Share for Carbapenems, 2014-2024
8.3 Carbapenem Market Forecast, 2014-2024
8.4 Trends in the Carbapenem Market
8.4.1 Rising Prevalence of Carbapenemases and ?-Lactamases
8.4.2 No New Carbapenems in Late-Stage Trials
8.5 Merrem/Meropenem
8.5.1 Generics Affecting Revenue Worldwide
8.5.2 Revenue Forecast 2014-2024
8.6 Primaxin
8.6.1 Combination Therapy for Lifecycle Management
8.6.2 Historic and Current Revenues
8.6.3 Revenue Forecast 2014-2024
8.7 Invanz
8.7.1 Revenue Forecast 2014-2024
8.8 Doribax
8.8.1 Doribax in HAP and VAP
8.8.2 Lifecycle Management in Japan and the Rest of the World
8.8.3 Revenue Forecast 2014-2024
9. Other Antibiotic Drugs: Forecast, 2014-2024
9.1 The Market for Other Classes of Antibacterial Drugs
9.2 Changing Market Share for Fluoroquinolone Antibacterials 2014-2024
9.3 Other Antibacterials: Market Forecast, 2014-2024
9.4 Trends in the Other Classes of Antibacterial Drugs
9.4.1 New Oxazolidinones Will Drive Growth
9.4.2 New Drug Classes to Drive Submarket Growth to 2023
9.5 Zyvox – The Market Leading Antibacterial
9.5.1 MRSA Activity Driving Revenue Growth
9.5.2 Promise in Tuberculosis and Anthrax
9.5.3 Patents, Litigation, and Competition – When and Who Will Produce Generic Linezolid?
9.5.4 Flat Growth to Patent Expiry, Revenue Forecast 2014-2024
9.6 Cubicin – The Leading Brand for ABSSSIs
9.6.1 Revenue Boosted by Approvals Worldwide
9.6.2 Patents, Litigation and Deals – How Long Will Market Exclusivity Last?
9.6.3 Sustained Growth through to 2017, Revenue Forecast 2014-2024
9.7 Tygacil – A Tetracycline With Many Approved Indications
9.7.1 Concerns Limiting Revenue Potential
9.7.2 Competition from Safer Novel Therapies Restricts Growth, Revenue Forecast 2014-2024
9.8 TOBI/TOBI Podhaler – The Market Leading Inhaler for Cystic Fibrosis
9.8.1 Historic and Current Revenue Performance
9.8.2 Approvals and Launches in New Markets to Drive Revenue Growth
9.8.3 Competition to Limit Long-term Growth, Revenue Forecast 2014-2024
9.9 Solodyn – A Treatment for Severe Acne
9.9.1 Generic Competition and Lifecycle Management
9.9.2 Limited Potential for Dermatology, Revenue Forecast 2014-2024
9.10 Vibativ – Limited Potential for Novel Lipoglycopeptide
9.10.1 Astellas Ends its Collaboration with Theravance
9.10.2 Limited HAP Label in the US – Revenue Forecast 2014-2024
9.11 Sirturo – A New Option for Multi-Drug Resistant TB
9.11.1 Chronic Treatment Schedule and Emerging Demand Drive Revenue Growth, Revenue Forecast 2014-2024
9.12 Tedizolid – Market Leading Follow-on to Zyvox?
9.12.1 Competition Increasing: Revenue Forecast 2014-2024
9.13 Oritavancin – An Antibiotic With a Novel PK Profile
9.13.1 Single Dose Differentiation to Deliver Market Share, Revenue Forecast 2014-2024
9.14 Dalbavancin – Competing in a Crowded Indication
9.14.1 Sustained Growth Over the Coming 10 Years, Revenue Forecast 2014-2024
9.15 Surotomycin – Cubist’s Second Treatment for C. difficile
9.15.1 Delayed Launch to Limit Potential, Revenue Forecast 2014-2024
9.16 Nemonoxacin – Taiwan’s Global Antibacterial Drug
9.16.1 Slow Initial Growth to Accelerate with US Approval, Revenue Forecast 2014-2024
10. The Leading National Markets, 2014-2024
10.1 The US and China Dominate the Global Antibacterial Market, But For Different Reasons
10.2 Above-Average Growth in US: Regional Forecasts, 2014-2024
10.3 China to Slump in Market Share, While Brazil and India Push on
10.4 Incidence of Infection by Country, 2013
10.4.1 Incidence of Pneumonia in National Markets – Pneumonia Predominant in America
10.4.2 Incidence of Community Acquired Urinary Tract Infections in National Markets – High Incidence Rate in the UK, US, and Spain
10.4.3 Incidence of Bacterial Skin and Skin Structure Infections in National Markets – Massive Potential in the US
10.4.4 Incidence of Upper Respiratory Tract Infections in National Markets – Europe Leads the Way
10.5 Antibacterial Drug Consumption by Nation, 2013
10.5.1 Antibacterial Drug Consumption in the Major National Markets
10.5.2 Antibacterial Drug Consumption in Minor National Markets
10.6 The Antibacterials Market in the US
10.6.1 The Continued Dominance of the US Market
10.7 The European Union the Second Largest Regional Market
10.7.1 Marginal Expansion in Antibacterial Spending – Market Forecast 2014-2024
10.7.2 Action to Encourage Antibacterial Drug Development in the EU
10.7.3 Italians Continue to Lead the Way in Antibiotic Use
10.7.4 The French Fascination with Expensive Antibacterial Drugs
10.7.5 Germany – Europe’s Antibiotic Steward
10.7.6 The Rising Use of Antibacterials Drugs Within the UK
10.7.7 Spanish Antibacterial Market to Grow Between 2018 and 2024
10.8 Japan – Still the Third Largest National Market
10.8.1 The Pause Before Growth in the Japanese Market
10.9 Will South Korea Continue Its High Use of Antibiotics?
10.10 BRIC Nation Sales Still Expanding – Market Forecast 2014-2024
10.11 Chinese Antibacterial Market Bloated by Reported Overuse
10.11.1 Developing Antibacterials in China, for China
10.11.2 Government Controls Subdue Recent Growth – Market Forecast 2014-2024
10.12 Indian Market to Expand by 50% Over the Coming Decade
10.12.1 Restricting Antibiotic Use in India
10.12.2 Sustained Expansion of the Indian Market, Forecast 2014-2024
10.13 Brazilian Antibacterial Market to Double in Size
10.13.1 Brazilian Market to Be Driven by Drug Resistance
10.14 Russia, TB Explosion to Drive Growth – Forecast 2014-2024
11. The Antibacterial Drug R&D Pipeline in 2014
11.1 Gram-Positive vs. Gram-Negative
11.2 A Pipeline Dominated by Small Molecule Drugs
11.3 Leading Phase III Pipeline Candidates Treatments
11.3.1 Ceftolozane-Tazobactam – Future Gram-Negative Blockbuster
11.3.2 Ceftazidime-Avibactam – Skipping Phase III Trials
11.3.3 Surotomycin – Broad C. difficile Treatment to Reduce Relapse
11.3.4 Tedizolid – More Potent Than Zyvox with Fewer Doses?
11.3.5 Oritavancin – Differentiated by Dosing
11.3.6 Delafloxacin – A Leading pH Activated, Broad Spectrum Fluoroquinolone
11.3.7 Dalbavancin – A Pharmacoeconomic Proposition
11.3.8 Solithromycin – A Fluroketolide Without the Side-Effects
11.3.9 Finafloxacin – A Second pH Activated Fluoroquinolone with Broad Spectrum Activity
11.3.10 Eravacyline – Treating Gram-Negative cUTIs and cIAIs
11.3.11 Plazomicin – Straight to PIII in Carbapenem Resistant Infections
11.3.12 Cadazolid: Largest PIII C. Difficile Trial
11.4 Leading Phase II Antibacterial Drug Candidates
11.4.1 AZD5847: An Oxazolidinone for TB
11.4.2 Avarofloxacin is Still Waiting for a Partner
11.4.3 MK-7655 and Invanz – A Novel ?-Lactamase Combination
11.4.4 Omadacycline – Another Phase III Ready Partnership
11.4.5 Radezolid – On Melinta’s Back-Burner for Now
11.4.6 AFN-1252: Highly Specific S. Aureus Antibacterial
11.4.7 Sutezolid – Sequella Looking to Combine TB Treatments
11.4.8 Taksta (Fusidic acid) – Cempra’s Second Pipeline Candidate
11.4.9 TD-1792 – A Russian Antibacterial
11.4.10 Brilacidin – A Novel Peptide Antibacterial Agent
11.4.11 POL7080 – Polyphor and Roche in Multi-Million Dollar Deal
11.4.12 BC-3781- Unique Mechanism of Action at 23S?
11.5 Inhaled Antibiotics – Advantages in Lung Infections
11.5.1 Cayston: Competition for Novartis?
11.5.2 ARIKACE – Targeting P. aeruginosa
11.5.3 Aeroquin – Better than Podhaler?
11.5.4 BAYQ3939 – Cystic Fibrosis? Not Anymore
11.5.5 NKTR-061: Targeting Intubated Pneumonia
11.5.6 Pulmaquin: A Second Ciprofloxacin Candidate
11.5.7 AeroVanc Targets MRSA Infections
11.5.8 Inhaled Amikacin-Fosfomycin – Adjunctive Therapy for VAP
11.6 Biologics – Truly Novel Antibacterial Therapeutics
11.6.1 MK-3415A: First Antibacterial mAb to the Market?
11.6.2 KB001A – The Leading Antibody Against P. aeruginosa
11.6.3 Aridis Pharmaceuticals: Targeting P. aeruginosa and S. aureus
11.6.4 MEDI4893 – Early Stage mAb to S. Aureus
12. Qualitative Analysis of the Antibacterials Market, 2014
12.1 SWOT Analysis: Strengths, Weaknesses, Opportunities, and Threats within the Antibacterial Drug Market
12.2 STEP Analysis: Social, Technological, Economic, and Political Factors Affecting the Antibacterial Drug Industry and Market
12.2.1 Social Factors
12.2.2 Technological Developments
12.2.3 Economic Pressures
12.2.4 Political Issues
12.3 Market is Well Established and Demand will Remain Strong
12.4 High Prevalence of Infection Worldwide
12.5 Worldwide Demand for Antibacterials Drugs
12.6 Animal Models of Infection are Highly Predictive Compared with Other Therapeutic Areas
12.7 Cutting Into a Saturated Market
12.8 Superior Benefit over Generics?
12.9 Resistance – Nature’s Patent Expiry
12.10 Acute Treatment Limits Commercial Potential
12.11 Did Big Pharma Back Away from Antibacterial Drugs?
12.12 Resistance Will Continue to Present New Targets
12.13 First Biologic Antibacterials
12.14 Potential for Smaller Firms to Capitalise
12.15 Developing Preventative Vaccines Rather Than Treatments
12.16 Antibacterial Stewardship Reduces Usage
12.17 Clinical Confusion from Inconsistent Guidance Between Regulatory Bodies
12.17.1 Therapeutic Success in European Clinical Trials
12.17.2 Poor Primary End Points in FDA Guidelines
12.18 Reduction in Hospital Infection Rates – Reducing Demand for Antibacterial Drugs
12.19 Enticing Antibacterial Drug Discovery – Push and Pull Incentives
12.19.1 GAIN act: Post-Development Pull Incentives in the US
12.19.2 ADAPT – Building on the GAIN act
12.19.3 EMA Update Guideline – Streamlining Clinical Trials in the EU
12.19.4 Push Incentives for Antibacterial Drug Discovery with Public Funding
12.19.5 IMI: Public-Private Collaboration with GSK and AstraZeneca
12.19.6 Public Finance Pumping Money into Antibacterial Development
13. Research Interviews from Our Survey
13.1 Interview with Dr Vu Truong, Founder & CSO, Aridis Pharmaceuticals, United States
13.1.1 Opportunities for Antibacterial Monoclonal Antibodies
13.1.2 Positioning Monoclonal Antibacterials in the Clinic
13.1.3 Differentiating Factor for Biological Antibacterials
13.1.4 Hazard Pitfalls in Clinical Development
13.1.5 Trends in Antibacterial Drug Market – Novel Targets Rewarded
13.1.6 The Commercial Hazard of Acute Therapeutics
13.1.7 Progress from Government Incentives, But More to Come on the Manufacturing Side
13.1.8 Bacteriophages, Potentially Innovative Therapeutics
13.2 Interview with Lyn Baranowski and Sue Cammarata, Melinta Therapeutics, United States
13.2.1 Opportunities in Treating Skin Infections and Gonorrhoea
13.2.2 Superior Effect in Overweight Populations
13.2.3 Focussing on the Domestic US Market
13.2.4 Anionic Activity Opens up Possibilities in treating cUTIs and cIAIs
13.2.5 Superiority Means Uptake Won’t be Restricted
13.2.6 Clear Regulatory Guidance Clears Paths to Development
13.3 Interview with Tetraphase Pharmaceuticals
14. Antibacterial Drugs Market to 2024: Conclusions
14.1 Three Blockbuster Antibacterials in 2013, Leading Brands of 2013
14.2 The Leading Branded Antibacterial Drugs in 2024
14.3 Signs of Life in the Antibacterial Pipeline
14.4 Stemming the Tide of Antibacterial Drug Resistance
14.5 The Changing Face of Antibacterial Clinical Development
【レポート販売概要】
■ タイトル：世界の抗菌薬市場（2014-2024）■ 英文：Antibacterial Drugs: World Industry and Market Prospects 2014-2024
■ 発行日：2014年3月
■ 調査会社：visiongain
■ 商品コード：Visiongain-4052642
■ 調査対象地域：グローバル
- オイルサンドの世界市場2015-2025The oil sands market will experience a dramatic downturn in 2015 as the impact of the oil price fall impacts upon project economics and company budgets. An almost equally significant decline will be seen in 2018 as the last under-construction oil sands mining and upgrading projects are completed. The extent to which oil sands investment recovers over subsequent years will be highly dependent upon …
- 紙コップ・紙容器の世界市場2017-2021ABSTRACTAbout Paper Cups and Containers Paper cups are usually coated with PE, which provides stability and heat resistance. However, these PE-coated paper cups are hard to recycle and do not decompose easily, which results in large amounts of paper cups piling up in landfills. Disposable containers are primarily made of paperboard, which is a little thicker than paper. These containers are usuall …
- 世界のPDM （製品データ管理）ソフトウェア市場About PDM PDM is one of the business functions within collaborative product definition management (cPDM), which is one of the major segments in the Global Product Lifecycle Management (PLM) market. PDM is a software responsible for the creation, management, and publication of product data. PDM helps organize product development by combining documents, technical data, computer-aided design (CAD), a …
- 世界の皮革用化学品市場：ウェットエンド皮革用化学品 、皮革仕上げ用化学品About Leather Chemicals Leather chemicals are a class of products used in the treatment of animal hides for the production of leather. There are a range of leather chemicals available in the market, which are deployed for every step in leather production - from beamhouse to finishing. The major categories of leather products include shoes, garments, furniture and automotive upholstery, and other a …
- Southwestern Energy Company：石油・ガスの開発・生産動向及びコスト分析– Q4, 2012Southwestern Energy Company Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2012 Summary Southwestern Energy Company Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an esse …
- 世界の食品保存剤市場動向と予測A wide range of preservatives can be used alone or in conjunction with other food preservation techniques. Some groups of preservatives target enzymes in fruits and vegetables that continue to metabolize after they are cut. Many food processing industries are focusing more on natural preservatives, as the possibility of health hazards with the consumption of foods preserved by chemical preservativ …
- 世界のインタラクティブホワイトボード市場動向（2012-2016）TechNavio's analysts forecast the Global Interactive Whiteboard market to grow at a CAGR of 6.9 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for dynamic interactive learning. The Global Interactive Whiteboard market has also been witnessing the adoption of interactive whiteboards in e-learning and virtual learning environment …
- ニコチン依存症(Nicotine Addiction)：治療薬開発パイプライン動向（2015年上半期版）Nicotine Addiction - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Nicotine Addiction - Pipeline Review, H1 2015’, provides an overview of the Nicotine Addiction’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Nicotine Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mecha …
- 世界のサルモネラ検査市場The report presents a detailed analysis of the Salmonella diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Salmonella definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - P …
- 婦人科用医療機器の世界市場：製品別（ハンドヘルド機器、画像診断機器、外科用機器、ソフトウェア）、地域別、競合別、セグメント予測The global gynecological devices market size is projected to reach USD billion 17.55 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 8.8% during the forecast period. Growing female population, increasing awareness levels pertaining to benefits of early diagnosis, and available treatments are anticipated to stoke the growth of the market. Rising prevale …
- ラフテレーンフォークリフトトラック(RTLT)の世界市場2018-2022About rough terrain lift truck (RTLT) Rough terrain lift truck (RTLT) are powered industrial trucks designed to lift and transfer material over short distances. These trucks are equipped to run on unpaved and rough surfaces and are suitable for construction sites or military applications. Technavio’s analysts forecast the Global rough terrain lift truck (RTLT) market to grow at a CAGR of 2.14% dur …
- 東南アジアのデータセンター冷却市場2016-2020About the Data Center Cooling Market in Southeast Asia Cooling solutions help lower the heat generated by IT equipment housed in data centers. Many computer room air conditioning (CRAC) and computer room air handling (CRAH) units are operated in data centers, including air conditioners, chillers, cooling towers, economizers, humidifiers, and modern containment systems that furnish rack cooling. Th …
- 抗菌塗料の世界市場2015-2019About Antimicrobial Coatings Antimicrobial coatings assist in maintaining surface quality and prevent the formation of cracks, bubbles, rust, fungus, and algae. These coatings inhibit the growth of pathogens on surfaces. Antimicrobial coatings are used in various applications in the fields of architecture, infrastructure, automotive, healthcare, textiles, food and beverages, and consumer durables. …
- 世界のVSaaS(Video Surveillance as a Service)市場動向（2012-2016）TechNavio's analysts forecast the Global Video Surveillance as a Service market to grow at a CAGR of 28.1 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for video surveillance. The Global Video Surveillance as a Service market has also been witnessing a growth because of the need for various companies to focus on their core act …
- 火傷治療の世界市場予測（～2021年）：アルギン酸、コラーゲン、ハイドロコロイド、ハイドロゲル・ドレッシングThe burn care market is expected to reach USD 2.33 Billion by 2021 from USD 1.68 Billion in 2016, at a CAGR of 6.8% from 2016 to 2021. In this report, the market has been segmented on the basis of product, depth of burn, end user, and region. Factors such as rising incidence of burn injuries, increasing healthcare expenditure, rising awareness on burn care, and advancements in burn care treatments …
